cp 115953 has been researched along with levofloxacin in 1 studies
Studies (cp 115953) | Trials (cp 115953) | Recent Studies (post-2010) (cp 115953) | Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) |
---|---|---|---|---|---|
20 | 0 | 0 | 4,346 | 581 | 2,209 |
Protein | Taxonomy | cp 115953 (IC50) | levofloxacin (IC50) |
---|---|---|---|
Replicase polyprotein 1ab | Betacoronavirus England 1 | 7.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
1 other study(ies) available for cp 115953 and levofloxacin
Article | Year |
---|---|
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |